BioGend Therapeutics Co., Ltd.
BioGend Therapeutics Co., Ltd. researches, develops, and sells orthopedic medical equipment and related products. It is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. The company was incorporated in 2016 and is based in Taipei, Taiwan.
Market Cap & Net Worth: BioGend Therapeutics Co., Ltd. (6733)
BioGend Therapeutics Co., Ltd. (TWO:6733) has a market capitalization of $10.55K (NT$349.06K) as of March 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #45038 globally and #1995 in its home market, demonstrating a -2.78% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioGend Therapeutics Co., Ltd.'s stock price NT$35.00 by its total outstanding shares 9973 (9.97K).
BioGend Therapeutics Co., Ltd. Market Cap History: 2025 to 2026
BioGend Therapeutics Co., Ltd.'s market capitalization history from 2025 to 2026. Data shows growth from $11.57K to $10.55K (0.00% CAGR).
BioGend Therapeutics Co., Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioGend Therapeutics Co., Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
BioGend Therapeutics Co., Ltd.'s market cap is 0.00 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $11.57K | $222.34 Million | -$84.61 Million | 0.00x | N/A |
Competitor Companies of 6733 by Market Capitalization
Companies near BioGend Therapeutics Co., Ltd. in the global market cap rankings as of March 18, 2026.
Key companies related to BioGend Therapeutics Co., Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
BioGend Therapeutics Co., Ltd. Historical Marketcap From 2025 to 2026
Between 2025 and today, BioGend Therapeutics Co., Ltd.'s market cap moved from $11.57K to $ 10.55K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$10.55K | -8.85% |
| 2025 | NT$11.57K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of BioGend Therapeutics Co., Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.55K USD |
| MoneyControl | $10.55K USD |
| MarketWatch | $10.55K USD |
| marketcap.company | $10.55K USD |
| Reuters | $10.55K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.